Larvol Delta - Provided-Positive-Interim-Results-of-Phase-1a-Single-SAD-and-Multiple-Ascending-Dose-MAD-Trial-of-Investigational-Bispecic-AntiTSLPIL4R-Antibody-ATI052

ATI-052 - Aclaris

https://www.globenewswire.com/de/news-release/2026/02/26/3245403/0/en/Aclaris-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html

Feb 26, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next